Начало・Списък с акции・Arcus Biosciences Inc

Arcus Biosciences Inc

Отворен

СекторЗдравеопазване

28.81 4.42

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

27.39

Максимум

28.58

Ключови измерители
By Trading Economics
Приходи	-22M -128M
Продажби	-16M 17M
EPS	-1.02
Марж на печалбата	-752.941
Служители	601
EBITDA	-42M -123M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+39.86% upside

Дивиденти
By Acuity
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	229M 3.5B
Предишно отваряне	24.39
Предишно затваряне	28.81

Настроения в новините

By Acuity

79%

21%

307 / 340 Класиране в Healthcare

Arcus Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:36 ч. UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31.07.2026 г., 23:16 ч. UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

30.07.2026 г., 18:03 ч. UTC

Arcus Biosciences Inc gains today, supported by a broader market uptick despite geopolitical tensions and inflation concerns. Shares pulled back from earlier session highs.

29.07.2026 г., 19:56 ч. UTC

Macro Event

Arcus Biosciences shares are lower amid broader market pressures from steady interest rates and rising crude oil prices, marking five consecutive sessions of decline.

28.07.2026 г., 20:06 ч. UTC

Arcus Biosciences Inc shares are lower today, reflecting broader market trends and declines in Asian markets, including significant losses in the Nikkei 225 Index.

27.07.2026 г., 21:01 ч. UTC

Arcus Biosciences Inc shares declined in after-market hours, continuing a downward trend over the last four sessions. No specific news was identified to explain the move.

24.07.2026 г., 19:06 ч. UTC

News

Arcus Biosciences has signed a clinical supply agreement with AVEO to evaluate casdatifan with tivozanib. Shares are trading lower, reflecting unusual weakness.

22.07.2026 г., 20:13 ч. UTC

Arcus Biosciences shares are higher in after-market hours. Broader market volatility is influenced by rising crude oil prices and geopolitical tensions.

21.07.2026 г., 19:36 ч. UTC

Arcus Biosciences shares are higher today, supported by overall market strength and positive sentiment in the biotechnology sector. The stock has advanced notably since Monday.

20.07.2026 г., 18:06 ч. UTC

News

H.C. Wainwright raised Arcus Biosciences' price target to $45 from $32, maintaining a Buy rating. Shares are higher today following the analyst's upgrade.

Сравнение с други в отрасъла

Ценова промяна

Arcus Biosciences Inc Прогноза

Ценова цел

By TipRanks

39.86% нагоре

12-месечна прогноза

Среден 38.63 USD 39.86%

Висок 47 USD

Нисък 22 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Arcus Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Arcus Biosciences Inc през последните 3 месеца.

Настроение

By Acuity

307 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.